Damm et al reported the integrative prognostic risk score (IPRS) for evaluating a patient with acute myeloid leukemia (AML) with a normal karyotype. This can help to identify a patient who may benefit from more aggressive management. The authors are from Hannover Medical School, Hubertus Wald University, University Hospital Hamburg-Eppendorf, University of Freiburg, University of Tubingen, Klinikum Ludenscheid and Erasmus University.
Patient selection: AML with normal karyotype
Parameters:
(1) age in years
(2) NPM1/FLT3 mutation status
(3) CEBPA mutation status
(4) WT1 SNP alleles
(5) BAALC expression
(6) white blood cell count in 10^9/L
(7) MN1 expression
(8) ERG expression
(9) WT1 expression
|
Parameters |
Findings |
Points |
|
age in years |
< 40 years |
0 |
|
|
>= 40 years |
3 |
|
NPM/FLT3 |
low risk |
0 |
|
|
high risk |
2 |
|
CEBPA mutation |
Mutated |
0 |
|
|
Nonmutated |
2 |
|
WT1 SNP |
not homozygous AA |
0 |
|
|
homozygous AA |
2 |
|
BAALC expression |
Low |
0 |
|
|
High |
2 |
|
WBC count |
< 25 * 10^9/L |
0 |
|
|
>= 25 * 10^9/L |
1 |
|
MN1 expression |
Low |
0 |
|
|
High |
1 |
|
ERG expression |
Low |
0 |
|
|
High |
1 |
|
WT1 expression |
Low |
0 |
|
|
High |
1 |
total score =
= SUM(points for all 9 parameters)
Interpretation:
• minimum score: 0
• maximum score: 15
|
Total Score |
Risk Group |
6-Year Overall Survival |
|
0 to 7 |
Low |
80% |
|
8 to 10 |
intermediate |
59% |
|
11 to 15 |
High |
21% |
Specialty: Hematology Oncology
